铁死亡抑制蛋白 1 (FSP1/AIFM2) 在癌症中的多种功能使其成为各种恶性肿瘤（包括头颈癌 (HNC)）的有前景的治疗靶点。由于其参与细胞凋亡和铁死亡，最初被定性为潜在的肿瘤抑制因子，最近的研究揭示了其在肿瘤生长、代谢和治疗耐药性中的复杂作用。 FSP1 的药理学抑制显示出使癌细胞对铁死亡敏感并克服对传统疗法的耐药性的潜力，为精准医学方法提供了新途径。鉴定新型 FSP1 抑制剂及其与现有疗法的协同作用为治疗开发提供了令人兴奋的机会。然而，将临床前研究结果转化为临床实践需要改进 FSP1 抑制剂、用于患者分层的强大生物标志物，并进一步研究 FSP1 介导的治疗耐药性的分子机制。将 FSP1 靶向疗法整合到综合治疗方案中有望改善癌症患者的治疗结果并推动精准肿瘤学领域的发展。版权所有 © 2024。由 Elsevier B.V. 出版。

The diverse functions of ferroptosis suppressor protein 1 (FSP1/AIFM2) in cancer have positioned it as a promising therapeutic target across various malignancies, including head and neck cancer (HNC). Initially characterized as a potential tumor suppressor due to its involvement in apoptosis and ferroptosis, recent studies have revealed its complex role in tumor growth, metabolism, and therapy resistance. Pharmacological inhibition of FSP1 shows potential in sensitizing cancer cells to ferroptosis and overcoming resistance to conventional therapies, offering new avenues for precision medicine approaches. Identifying novel FSP1 inhibitors and their synergistic effects with existing therapies presents exciting opportunities for therapeutic development. However, translating preclinical findings into clinical practice requires the refinement of FSP1 inhibitors, robust biomarkers for patient stratification, and further investigations into the molecular mechanisms underlying FSP1-mediated therapy resistance. Integrating FSP1-targeted therapies into comprehensive treatment regimens holds promise for improving outcomes in cancer patients and advancing the field of precision oncology.Copyright © 2024. Published by Elsevier B.V.